CareDx, Inc Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022
January 09, 2023 at 05:30 pm IST
Share
CareDx Inc. provided revenue guidance for the fourth quarter and full year ended December 31, 2022. For the quarter, the Preliminary revenue for the three months ended December 31, 2022, is expected to be between $81.9 million and $82.2 million, an increase of approximately 4% compared with $79.2 million in the fourth quarter of 2021.
For the Full Year 2022, preliminary revenue is expected to be between $321.3 million and $321.6 million, an increase of approximately 8% compared with $296.4 million in 2021.
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Companyâs product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
CAREDX, INC 
